What is Ginkgo Bioworks's stock-based comp?

Ginkgo Bioworks (DNA) reported stock-based comp of $15.85M in Q1 2026.

How has Ginkgo Bioworks's stock-based comp changed year-over-year?

Ginkgo Bioworks's stock-based comp decreased by 8.8% year-over-year, from $17.39M to $15.85M.

What is the long-term trend for Ginkgo Bioworks's stock-based comp?

Over 4 years (2021 to 2025), Ginkgo Bioworks's stock-based comp has grown at a -52.5% compound annual growth rate (CAGR), from $1.61B to $81.55M.

What does stock-based comp mean?

Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.

Ginkgo Bioworks DNA Stock-Based Comp

Stock-Based Comp at other companies

Thermo Fisher ScientificTMO

$83M+10.7%

Charles River LaboratoriesCRL

$22.38M+70.4%

AbCellera Biologics Inc.ABCL

$12.01M-18.8%

TEC

Bio-TechneTECH

$10.5M-7.9%

AzentaAZTA

$6.36M-23.7%

RegenxbioRGNX

$8.62M+0.9%

Segments

By segment

See full

Biosecurity$2.62M—

Other financials

Income statement

See full

Revenue$19.5M-49.1%

Gross profit$16.4M-52.0%

Operating income-$71.4M+11.9%

Net income-$82.6M+9.2%

EPS (diluted)-$1.42+27.6%

Balance sheet

See full

Cash & equivalents$188.7M-46.9%

Total debt$410.7M-5.5%

Total equity$443.2M-31.6%

Total assets$1.0B-20.1%

Cash flow

See full

Operating cash flow-$46.7M+9.4%

CapEx$1.9M-74.6%

Free cash flow-$48.6M+17.8%

Valuation

See full

Market cap$625.16M+24.6%

Enterprise value$847.19M+45.9%

P/S4.4×+2.2×

Profitability

See full

Operating margin-210.7%+7.6pp

Net margin-215.4%+8.3pp

FCF margin-119%-21.2pp

Returns & leverage

See full

Return on equity-55.8%-1.8pp

Debt / equity0.9×+0.3×

Current ratio5.2×+0.3×

Where this comes from

Reported directly by Ginkgo Bioworks in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: Ginkgo Bioworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ginkgo Bioworks's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Ginkgo Bioworks's stock-based comp?: Ginkgo Bioworks (DNA) reported stock-based comp of $15.85M in Q1 2026.
How has Ginkgo Bioworks's stock-based comp changed year-over-year?: Ginkgo Bioworks's stock-based comp decreased by 8.8% year-over-year, from $17.39M to $15.85M.
What is the long-term trend for Ginkgo Bioworks's stock-based comp?: Over 4 years (2021 to 2025), Ginkgo Bioworks's stock-based comp has grown at a -52.5% compound annual growth rate (CAGR), from $1.61B to $81.55M.
What does stock-based comp mean?: Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.